news
SMi’s 13th Annual ADMET conference 2018 brochure released
The annual ADMET conference is returning to London, UK for its 13th year running and will be taking place at the Holiday Inn Kensington Forum on the 9 and 10 July 2018...
List view / Grid view
toxicology
article
Expert view: Conquering late stage failures with advanced hit-to-lead techniques
Failing early in drug discovery is the primary driving force for new techniques in the hit-to-lead phase.
article
Identification of hits and leads for human African trypanosomiasis
Neglected tropical diseases (NTD) affect more than one billion people and new targets and drugs are needed to tackle these infections. The multi-disciplinary NMTrypI consortium has identified a number of different compound classes which could be effective against these diseases. This article reviews some of these compounds...
news
Prenatal exposure to BPA at low levels can affect gene expression
Prenatal exposure to BPA affects gene expression related to sexual differentiation and neurodevelopment in the developing brain...
news
New botulinum neurotoxin discovered
Researchers have identified a new toxin, botulinum neurotoxin type X (BoNT/X), that has the potential to open up a new field of toxin therapeutics...
news
Balance and movement improved in animal model of Parkinson’s disease
Researchers have developed a molecular compound that improves balance and coordination in mice with early stage Parkinson's disease.
webinar
The mast cell receptor MrgX2 and drug-induced anaphylaxis
10 May 2017 | By DiscoverX
The goal of this webinar is to illustrate how knowledge of MrgX2 activity across a panel of mammalian species can be integrated into drug development to influence choice of compound, species model and dosing regimen...
news
Novel method to detect toxic effects of chemicals could reduce need for animal testing
Traditional toxicological investigations performed on animals (in vivo) are expensive, time-consuming and may cause animal suffering.
news
Sound Pharmaceuticals receives $1.6 Million Award to treat CF-related tinnitus
Sound Pharmaceuticals has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
news
StemTek and tebu-bio announce European partnership for Cell2Sphere
Cell2Sphere is the first simple 3D tissue culture kit for labs interested in more accurate, scalable and dynamic experimental research.
news
Benzodiazepines increase stroke risk in Alzheimer’s patients
The use of benzodiazepines and benzodiazepine-like drugs was associated with a 20% increased risk of stroke among persons with Alzheimer’s disease, shows a recent study from the University of Eastern Finland.
news
Advancing non-animal testing methods: EC publishes tool guidance
30 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The AOPs are knowledge management tools in toxicology and are useful for supporting risk assessment to human health and to increase non-animal testing...
article
A picture is worth a thousand endpoints: high-content imaging in drug discovery
Over the past few years several factors in the drug discovery industry have come together to drive an increased interest and subsequent surge in the use of high-content imaging. These include the high costs of attrition in the clinic due to lack of efficacy; increased hurdles and rising costs to…
article
Zebrafish early-life stages as neurological screening and detection tools
Unforeseen efficacy and safety-related issues with drugs continue to be a major cause of their attrition, despite significant efforts that are expended to eliminate them prior to initiating clinical trials...
article
Pharmacometabolomics as the key to personalised medicine
Blanketed administration of drugs to all populations assumes that all patients respond similarly. Despite pharmaceutical companies’ efforts to develop drugs with large therapeutic windows, there are often and inevitably subpopulations of individuals who will either not respond to therapy or will respond with adverse effects...
